Several companies, including SeaStar Medical, Leslie's, and Liftoff Mobile, have released their Q2 2026 earnings, with mixed results regarding EPS and revenue targets. Additionally, previews for Q2 2026 earnings were provided for Global Water Resources, MediWound, and Tecogen.

Analysts have raised price targets for both Energy Transfer (ET) and Humacyte, Inc. (HUMA), despite mixed first-quarter results for ET and Humacyte's early-stage commercialization.

Humacyte (HUMA) has published its earnings transcript for the first quarter of 2026, detailing the company's financial performance and operational updates.

BTIG has lowered its price target for Humacyte (HUMA) but continues to hold a bullish view on the company's long-term opportunities.

Humacyte has secured a $1.48 million commitment for the purchase of its Symvess product in Saudi Arabia, marking a significant business development.

Humacyte has priced its $50 million public offering of common stock at $1.05 per share.

Analysts are expressing conflicting opinions regarding the healthcare companies Cullinan Management (CGEM), Humacyte (HUMA), and Revvity (RVTY).

Humacyte has released highlights from its first-quarter earnings call, detailing the company's financial and operational updates.

Humacyte reported its Q4 GAAP EPS of -$0.13, which was in-line with expectations, but its revenue of $0.47 million missed estimates, with further details emerging from its earnings call.

Several companies, including Groupon, Ani, 1stdibs, Lensar, TeraWulf, TTEC, Interface, i3 Verticals, Ultralife, and AirSculpt, have released transcripts for their Q1 2026 and Q4 2025 earnings calls, detailing their financial results and operational discussions.

Humacyte has announced that it has regained the ex-U.S. rights to its product Symvess from Fresenius Medical Care.

A preview of Super League's financial performance for the fourth quarter of 2025 has been released.